GDF-8 identity testing rests on several independent checks, not a single number. Intact mass by LC-MS fixes the molecular weight of the construct. Peptide mapping confirms the sequence. Non-reducing analysis shows the disulfide-linked dimer. Purity by RP-HPLC area percent tells you how much of one thing is present, never which thing.
- GDF-8 is myostatin, encoded by MSTN as a 375-residue precursor whose C-terminal 109-residue mature domain forms a disulfide-linked homodimer.
- A purity percentage measures chromatographic homogeneity and carries no information about molecular identity.
- Intact mass by LC-MS should be reported under both reducing and non-reducing conditions, since the dimer and monomer answer different questions.
- Peptide mapping with tandem MS, reported with enzyme and sequence coverage, is the primary identity test for a protein of this size.
- Isobaric substitutions and scrambled disulfide connectivity are invisible to intact mass measurement.
- No recombinant GDF-8 product is approved as a medicine by any major regulator as of August 26, 2026.
What this guide covers
This guide is about one question: does a vial labeled GDF-8 hold the molecule it claims to? It explains why a purity figure cannot answer that, what intact mass and peptide mapping each prove, how to read the certificate line by line, and how to keep the material intact once it arrives.
In plain terms, it is like confirming a coupled pair of train cars. You weigh the whole set, read the serial plates on each car, and check the coupling that holds them together. Intact mass, peptide mapping and non-reducing analysis do those three jobs for the GDF-8 dimer.
- Peptide map with MS/MS and stated coverage — sequence confirmed
- Intact mass, reduced and non-reduced — molecular weight and covalent dimer
- N-terminal sequencing — processing and terminal integrity
- SEC and non-reducing gel — oligomeric state
- Cell-based reporter assay — the fold is functional
- Purity area percent — homogeneity only, no identity claim
Which molecule does a GDF-8 label actually mean?
GDF-8 is myostatin, the product of the MSTN gene and a member of the TGF-β superfamily. In humans the gene encodes a 375-residue precursor. That precursor carries a signal peptide, a large N-terminal propeptide, and a C-terminal mature domain of 109 residues released by furin-type cleavage at a basic recognition site. The mature domain assembles as a disulfide-linked homodimer built around a cystine knot, and after cleavage the propeptide stays associated non-covalently, holding the dimer in a latent complex until that association is disrupted.
All of which means the string "GDF-8" on a vial label is under-specified. It could describe the mature homodimer, a reduced monomer, the propeptide alone, the latent complex, an N-terminally extended construct carrying an initiator methionine or an affinity tag, or a short synthetic fragment of the sequence that happens to share the name. These are different molecules with different masses, different chromatographic behavior and different reference materials. An identity test that does not state which one it examined has not established identity.
Expression system matters for the same reason. Material produced in E. coli is non-glycosylated and has usually been refolded from inclusion bodies; material from CHO or HEK cells may carry glycans and will show mass heterogeneity that an E. coli product does not. A certificate that reports a single sharp intact mass for a mammalian-expressed glycoprotein is describing something other than what it claims to describe.
The recurring failure in this corner of the supply chain is a synthetic-peptide document set applied to a protein. RP-HPLC area percent plus a single ESI-MS spectrum is a reasonable package for a 30-residue synthetic sequence. For a 12 kDa disulfide-bonded dimer it leaves the folding state, the oligomeric state and the sequence itself unaddressed.
Does a purity percentage confirm identity?
The number most buyers look at first is the least informative one on the page. "98.2% by HPLC" means that 98.2 percent of the ultraviolet absorbance integrated across the chromatogram fell under the main peak, at whatever wavelength, gradient, column and load the operator chose. It is a statement about homogeneity. It says nothing at all about what the main peak contains.
Several things follow from that. Detection at 214 nm responds to the peptide bond and sees essentially everything peptidic; detection at 280 nm responds to tryptophan and tyrosine and will under-report species poor in aromatics. Neither sees counterions, residual salts, water, or organic residues from synthesis or purification. A lyophilizate that is 98 percent pure by area can be a third trifluoroacetate and water by mass, and both figures are true simultaneously.
ICH Q6B treats identity and purity as separate specification categories for exactly this reason, and expects an identity test to be sufficiently specific to distinguish the product from closely related molecules. Area percent cannot do that. Two proteins of similar hydrophobicity co-elute routinely. A scrambled-disulfide isomer of the correct sequence may elute as a shoulder, or may not resolve at all under a standard gradient.
Treat the purity figure as one row of a table rather than the headline. The rows above it are the ones carrying the identity argument.
What does intact mass by LC-MS prove, and what does it miss?
Electrospray ionization of an intact protein produces a charge envelope, a series of multiply protonated ions across a range of m/z values. Deconvolution converts that envelope into a neutral mass. For a 12 kDa protein on a modern high-resolution instrument, agreement within one or two daltons of the calculated average mass is a reasonable expectation; quoting parts-per-million accuracy figures borrowed from small-molecule work is optimistic at this size and with this kind of sample handling.
The reduced and non-reduced measurements answer different questions and both belong on the report. Reducing the sample collapses the dimer to monomer and adds two hydrogens per disulfide broken. Running the sample intact should show the covalent dimer.
The arithmetic for a mature human GDF-8 construct, with the caveat that the exact figure depends on the construct and should be recalculated from the supplier's stated sequence:
reduced monomer, calculated average mass ≈ 12,400 Da
dimer = (2 × 12,400) − (5 disulfides × 2 H) ≈ 24,790 Da
Four intrachain disulfides in the cystine knot plus one interchain bond gives five per dimer, so ten hydrogen atoms are lost relative to twice the reduced monomer. Seeing a mass near 24,790 under non-reducing conditions and near 12,400 after reduction is decent evidence that the covalent architecture is what it should be.
What intact mass cannot resolve is the part people forget. Leucine and isoleucine are isobaric. Aspartate and isoaspartate are isobaric. Any permutation of the same residues has the same mass, and so does any disulfide connectivity built from the same cysteines. A completely mis-paired, functionally dead cystine knot weighs exactly what the correct one weighs. Intact mass narrows the field. It does not close it.
How does peptide mapping confirm the sequence?
Peptide mapping is the workhorse identity test for a protein of this size and is described as such in USP General Chapter <1055>. The protein is denatured, usually reduced and alkylated, then digested with a specific protease. Trypsin, cleaving C-terminal to lysine and arginine, is the default; Glu-C or chymotrypsin is used as a second enzyme where trypsin leaves gaps. The resulting fragments are separated by RP-HPLC and identified by tandem mass spectrometry.
A useful map report tells you four things: which enzyme or enzymes were used, the percentage sequence coverage achieved, whether both termini were observed, and whether the map was compared against a digest of a qualified reference standard run in the same sequence. Coverage in the high nineties with observed N- and C-terminal peptides is a strong identity result. Coverage of sixty percent with unobserved termini leaves the possibility of a truncation or an unexpected extension sitting exactly in the blind spot.
Terminal confirmation deserves separate attention for GDF-8 because the mature domain is defined by a proteolytic cleavage. If the construct was expressed as a precursor and processed, incomplete or ragged processing shifts the N-terminus. Edman degradation on the first five to ten residues is still used for this and gives an orthogonal read independent of the mass spectrometer. For the mature human sequence the first residues run Asp-Phe-Gly-Leu-Asp, which is a short and unambiguous fingerprint.
Disulfide mapping is the harder variant and is worth asking for when folding is in question. Digestion under non-reducing conditions, at a pH low enough to suppress thiol-disulfide exchange, preserves the bonds and lets the linked peptide pairs be identified by mass. This is the only routine method that distinguishes correct connectivity from scrambled connectivity. Most research-grade certificates do not include it.
What can each analytical method conclude?
| Method | What it measures | Identity evidence? | Common limitation |
|---|---|---|---|
| RP-HPLC, area percent | Chromatographic homogeneity | No, on its own | Blind to co-eluting species and to non-absorbing content |
| RP-HPLC, retention time vs reference | Comparative behavior | Weak, supporting only | Retention shifts with column age, temperature, gradient |
| Intact LC-MS, reduced | Monomer molecular weight | Yes, partial | Isobaric substitutions and permutations invisible |
| Intact LC-MS, non-reduced | Covalent dimer mass | Yes, partial | Says nothing about which cysteines pair |
| Peptide mapping with MS/MS | Sequence, coverage, termini | Yes, primary | Gaps in coverage hide local defects |
| Non-reducing SDS-PAGE | Apparent size of covalent species | Supporting | Cystine-knot proteins migrate anomalously |
| Size-exclusion HPLC | Dimer, monomer, aggregate distribution | Supporting | Column chemistry can adsorb or dissociate species |
| Cell-based reporter assay | Receptor engagement and downstream signaling | Functional, not structural | Cell-line and passage dependent; wide confidence intervals |
Two entries in that table deserve a note. SDS-PAGE apparent molecular weight is routinely off for cystine-knot proteins, and a band running at 26 or 28 kDa rather than 25 is not by itself a finding. It is a shape effect. Reading a gel as if it were a mass measurement is a habit worth breaking.
The bioassay is the only method listed that reports on folding. A reporter line carrying a SMAD-responsive luciferase construct responds to receptor engagement, and correctly folded material produces a dose-response curve while scrambled material does not. Mass spectrometry cannot make that distinction. If the intended work depends on the protein being active rather than merely present, a functional result on the specific lot is the evidence that matters, and its absence should be treated as an open question rather than an assumption.
What should each line of a GDF-8 certificate show?
| Field | Adequate | Red flag |
|---|---|---|
| Product description | Species, residue range, expression host, tag status | "GDF-8 (Myostatin)" and nothing else |
| Lot number | Unique, appears on vial and document | Absent, or a generic catalog number reused |
| Test dates | Each method dated, after the fill date | Undated, or predating manufacture |
| Intact mass | Observed and calculated, reduced and non-reduced | A single figure with no conditions stated |
| Peptide map | Enzyme, coverage percentage, termini observed | "Confirmed by MS" with no data |
| Purity | Method, wavelength, gradient, area percent | A bare percentage |
| Oligomeric state | SEC or non-reducing gel result | Not addressed |
| Endotoxin | EU/mg with method named | Omitted for a bacterially expressed protein |
| Residual moisture and counterion | Reported as percent by mass | Omitted, leaving net protein content unknown |
| Signature | Named analyst or QC release | Unsigned template |
Raw data separates a real certificate from a formatted assertion. Ask for the deconvoluted mass spectrum, the annotated peptide map and the chromatogram with its axes legible. A supplier who runs the tests has these files sitting in a folder. A supplier who buys documentation with the material will find reasons not to send them, and the reasons are usually about confidentiality.
One more field is worth requesting even though it rarely appears: net peptide or net protein content. Between counterion, residual water and any excipient, the mass in the vial is not the mass of protein in the vial. If a protocol depends on knowing the actual quantity, that number has to come from amino acid analysis or a quantitative UV measurement, not from the label weight. Our quality standard page sets out which of these tests we require per lot and which are run on a periodic basis.
How to check a GDF-8 certificate, step by step
Work through the certificate in this order. Each step uses figures and fields covered above.
- Pin down the construct. The product description should give species, residue range, expression host and tag status. Get the exact construct sequence, including any tag or initiator methionine, so you can recalculate the expected mass yourself.
- Match the lot. The lot number has to be unique and appear on both the vial and the document.
- Check the dates. Each method should be dated, and every date should fall after the fill date.
- Read the intact mass. Look for observed and calculated values under both reducing and non-reducing conditions, near 12,400 Da for the reduced monomer and near 24,790 Da for the dimer of a mature human construct.
- Find the peptide map. It should name the enzyme, give the coverage percentage and say whether both termini were observed.
- Read purity last. It needs the method, wavelength and gradient beside the area percent.
- Check the remaining rows: oligomeric state by SEC or non-reducing gel, endotoxin for a bacterially expressed protein, and residual moisture and counterion as percent by mass.
- Ask for the raw files: the deconvoluted mass spectrum, the annotated peptide map and the chromatogram with legible axes.
Red flags on a GDF-8 certificate
- "GDF-8 (Myostatin)" as the whole product description, with no species, residue range, host or tag status.
- A bare purity percentage with no method behind it, or purity offered as the identity result.
- "Confirmed by MS" with no data, or a single mass figure with no conditions stated.
- One sharp intact mass reported for a mammalian-expressed glycoprotein. That is an internal inconsistency worth asking about.
- No endotoxin result on a bacterially expressed protein.
- Undated tests, tests dated before manufacture, or an unsigned template.
- A refusal to send the underlying data files, usually framed around confidentiality.
How should the material be handled so the identity result holds?
A verified certificate describes the vial as it left the analytical laboratory. Everything after that is on the receiving lab. For a disulfide-bonded, refolded protein the two practical risks are aggregation and thiol-disulfide exchange, and both are accelerated by the same things: elevated temperature, agitation, and alkaline pH.
Free thiols catalyze disulfide rearrangement, and a protein with five disulfide bonds and any residual free cysteine content has the substrate for it. Reducing agents attack the same bonds, which is why they work against the native fold.
The broader storage argument, including why moisture rather than freezer temperature is the dominant variable for a dry solid, is set out in the storage and stability guide and applies here without modification.
Record the lot identifier against every vial and every result. When a result looks wrong, the first thing anyone will want to know is whether the material was what the protocol assumed, and a chain of records back to the certificate answers that faster than repeating the experiment.
What is the regulatory status of GDF-8?
Myostatin was described by McPherron, Lawler and Lee in 1997 as a TGF-β superfamily member that negatively regulates skeletal muscle mass in mice. It has since been a target for pharmaceutical development programs, several of which have been discontinued. No product consisting of recombinant GDF-8 protein is approved by the FDA, EMA or any comparable authority for human use, and material supplied for laboratory work carries no such authorization.
Agents acting on this pathway also appear on the World Anti-Doping Agency Prohibited List under hormone and metabolic modulators, which is context for why the compound attracts interest outside research settings. That interest does not change what the material is or what its documentation covers.
Status verified August 26, 2026.
FOR LABORATORY AND IN-VITRO RESEARCH USE ONLY. NOT FOR HUMAN OR ANIMAL CONSUMPTION. NOT FOR PERSONAL, MEDICAL, DIAGNOSTIC, THERAPEUTIC, OR RECREATIONAL USE.
Bottom line
For GDF-8, identity is a stack of checks. Intact mass under reducing and non-reducing conditions fixes the molecular weight. Peptide mapping with tandem MS confirms the sequence. Folding is a separate matter that only a cell-based assay on the specific lot speaks to. The purity percentage measures homogeneity and nothing more, so read it as one row of the table. Match the lot, ask for the raw data, and treat any missing test as an open question.
What is GDF-8 studied for?
Published research on GDF-8 investigates the areas below, which is a different question from what GDF-8 will do for anyone, a claim about a living system that nothing on this site is sold for.
What it is. Growth/differentiation factor 8, also called myostatin — a member of the TGF-beta superfamily.
What the research looks at. Extensively characterized as a target for inhibition in muscle-wasting conditions. Note the direction: the research interest is in blocking GDF-8, not in supplying it.
How it is thought to work. A secreted negative regulator of skeletal muscle growth, expressed specifically in developing and adult skeletal muscle, signalling through activin type II receptors.
What is not established. No approved product.
The full record, including the certificate for the lot in stock, is on the GDF-8 product page.
Common questions
Is an ESI-MS spectrum enough to confirm GDF-8 identity?
Why does the certificate list a mass around 25 kDa when the sequence is 109 residues?
What does 98% purity actually guarantee?
Can mass spectrometry tell me whether the protein is correctly folded?
Does expression host change what identity testing should look like?
What should I ask a supplier for beyond the certificate?
More documentation guides
Sources
- McPherron, Lawler and Lee, Nature, 1997. Original description of GDF-8/myostatin as a TGF-β superfamily member regulating skeletal muscle mass in mice; supports the identification of the gene product and its family placement.
- UniProt Knowledgebase entry for human myostatin (MSTN). Curated precursor length, signal peptide and propeptide boundaries, furin processing site and mature domain sequence; supports the residue numbering and the mature N-terminal fingerprint.
- ICH Q6B, Specifications: Test Procedures and Acceptance Criteria for Biotechnological/Biological Products. Establishes identity and purity as separate specification categories and sets the expectation that an identity test be specific enough to distinguish the product from closely related molecules.
- USP General Chapter <1055>, Biotechnology-Derived Articles — Peptide Mapping. Describes peptide mapping as an identity test, including digestion conditions, separation and comparison against a reference digest.
